Patients are Our Passion

Treatment of chronic rhinosinusitis (CRS) requires additional innovations, including in methods of delivery to the site of inflammation. Paratek is committed to reaching both specialists and primary care providers to address the unmet patient needs in CRS.

"Antimicrobial resistance (AMR) is a critical, global public health issue and an ongoing pandemic. Efforts to combat AMR require a multi-pronged approach, including responsible antibiotic use, improved surveillance, research into new antibiotics, and policy changes to enable a vibrant marketplace that recognizes the life-saving value of novel antibiotics. Paratek is a biopharmaceutical company that is dedicated to addressing AMR, a critical concern for public health and national security."

Paratek provides innovative therapies for specialists and community care providers. Our portfolio of products help address public health threats and important unmet medical needs.